" "@en . . . "Ramoplanin is the first in a new class of antimicrobials to reach clinical trials. It is a glycolipodepsipeptide produced by the fermentation of Actinoplanes spp.. Ramoplanin blocks bacterial cell wall biosynthesis by interfering with peptidoglycan production. Ramoplanin inhibits the N-acetylglucosaminyltransferase-catalysed conversion of lipid intermediate I to lipid intermediate II, a step that occurs before the transglycosylation and transpeptidation reactions. Ramoplanin\u2019s mechanism of action is distinct from that of glycopeptides. Unlike glycopeptides, ramoplanin does not complex with the D-Ala\u2013D-Ala sequence of cell wall precursors."@en . . "Ramoplanin"@en . . . . . . "For the treatment of bacterial infections."@en . . "No/limited absorption."@en . "76168-82-6"@en . . . . . . . "# Fang X, Tiyanont K, Zhang Y, Wanner J, Boger D, Walker S: The mechanism of action of ramoplanin and enduracidin. Mol Biosyst. 2006 Jan;2(1):69-76. Epub 2005 Nov 29. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/16880924 # Fulco P, Wenzel RP: Ramoplanin: a topical lipoglycodepsipeptide antibacterial agent. Expert Rev Anti Infect Ther. 2006 Dec;4(6):939-45. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17181409"@en . "investigational"@en . . . . . . . "Ramoplanin is a novel glycolipodepsipeptide antibiotic under development for the treatment of CDAD."@en . . . . . . . . . "Gram-positive Bacteria"@en . . .